Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients (VECODUE)
VECODUE A Phase II Trial of Vemurafenib Plus Cobimetinib in Patients Treated With Prior First-line Systemic Immunotherapy for Inoperable Locally Advanced or Metastatic Melanoma
Sponsor: Fondazione Melanoma Onlus
Terminated
low enrolment rate
This PHASE2 trial investigates Melanoma and Melanoma (Skin) and is currently terminated or withdrawn. Fondazione Melanoma Onlus leads this study, which shows 10 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
May 2021 — Feb 2023 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Apr 2020 — Aug 2020 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Apr 2020 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fondazione Melanoma Onlus
- Roche Pharma AG
For direct contact, visit the study record on ClinicalTrials.gov .